InnoCare Pharma Limited

InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.

อุตสาหกรรม

Biotechnology

ภาคส่วน

Healthcare

สำนักงานใหญ่

CN

ซีอีโอ

Jisong Cui

จดทะเบียนตั้งแต่

23 มี.ค. 2563

พนักงาน

1,176